MedPath

18F-PSMA PET/CT for visualization of glioblastoma multiforme

Phase 2
Recruiting
Conditions
glioblastoma multiforme
high grade glioma
10029211
Registration Number
NL-OMON48577
Lead Sponsor
Radboud Universitair Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
5
Inclusion Criteria

- Suspected GBM on MRI scan, - Scheduled for tumor resection at Radboudumc, -
Age *18 years

Exclusion Criteria

- Age < 18 years, - Pregnancy or the wish to become pregnant within 6
months, - Creatinine clearance below 40ml/min, - Liver disease defined as
aspartate aminotransferase or alanine aminotransferase level of more than three
times the upper limit of normal range

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>* The uptake of 18F-PSMA PET/CT in suspected GBM lesions<br /><br>These data will be presented in a quantitative way. Activity is determined in a<br /><br>volume of interest (VOI) based on a relative threshold (>70% of the maximum<br /><br>voxel value within the VOI : VOI70%). Maximum standardized uptake in this VOI<br /><br>(SUVmax) and target to background ratios (TBR) are determined. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>* The correlation between PSMA protein and RNA expression with 18F-PSMA PET/CT<br /><br>uptake.<br /><br>PSMA protein and RNA expression will be presented in a quantitative way (FPKM<br /><br>as determined in targeted RNAsequencing analysis), and it will be plotted<br /><br>against 18F-PSMA uptake (SUVmax). Correlation will be described with the<br /><br>Pearsons correlation coefficient.<br /><br><br /><br>* Correlation between 18F-PSMA PET/CT and T1GdMRI<br /><br>Qualified radiologist and nuclear medicine physician will review the images and<br /><br>compare them qualitatively (tumor delineation etc).</p><br>
© Copyright 2025. All Rights Reserved by MedPath